
Viscosupplementation for Knee Osteoarthritis - Rheumatology Advisor
Mar 25, 2019 · Viscosupplementation is one of those treatment options. What is Viscosupplementation? Viscosupplementation is a medical procedure during which a gel-like fluid called hyaluronic acid is …
Viscosupplementation is a medical procedure during which a gel-like fluid called hyaluronic acid is injected into the knee joint. Hyaluronic acid is a naturally occurring lubricant that allows for smoother …
ACR and AAHKS to Release Guidelines for Optimal Timing of Total …
Apr 5, 2023 · The ACR and AAHKS developed consensus-based recommendations for the optimal timing of performing TJA among patients with OA or osteonecrosis.
Guidelines for Optimal Timing of Total Joint Arthroplasty for ...
Oct 20, 2023 · When the efficacy of nonoperative treatments for osteoarthritis or osteonecrosis diminishes, patients often choose arthroplasty as a means to alleviate pain and restore function. …
Superior Reduction in Osteoarthritis Knee Pain From Novel Hyaluronan ...
May 18, 2017 · “Viscosupplementation with hyaluronan is a well-established treatment option for knee osteoarthritis. The goal of viscosupplementation is to reduce pain and improve viscoelasticity of …
Ortho Dx: What grade of arthritis does this patient have?
Aug 22, 2017 · Viscosupplementation, or hyaluronic acid injections, are gel-like injections for the knee that provide lubrication and pain relief for patients with knee arthritis.
ACR Releases Guidance on Managing VEXAS Syndrome
Sep 2, 2025 · The ACR recently issued the first formal international consensus guidance statement on diagnosing and managing VEXAS syndrome.
Lorecivivint Shows Promising Efficacy for Managing Knee Osteoarthritis ...
Nov 19, 2024 · Lorecivivint was effective for managing symptoms of moderate to severe knee OA while providing structural benefits.
Conservative Management Options for Osteoarthritis
Apr 25, 2016 · Osteoarthritis is one of the most common problems encountered in primary care, and conservative treatment can improve patients' quality of life.
- [PDF]
Rheumatology Advisor
Current Biologic Therapies for EGPA Latest results Benralizumab, which targets the IL-5 receptor and elicits a natural killer cell- mediated antibody-dependent response against eosinophils, is being …